YMTX vs. PTIX, KA, KTRA, PCSA, AIMD, HOTH, HILS, IBIO, LIXT, and XBIO
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Protagenic Therapeutics (PTIX), Kineta (KA), Kintara Therapeutics (KTRA), Processa Pharmaceuticals (PCSA), Ainos (AIMD), Hoth Therapeutics (HOTH), Hillstream BioPharma (HILS), iBio (IBIO), Lixte Biotechnology (LIXT), and Xenetic Biosciences (XBIO). These companies are all part of the "pharmaceutical preparations" industry.
Protagenic Therapeutics (NASDAQ:PTIX) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings, media sentiment and community ranking.
Protagenic Therapeutics has a net margin of 0.00% compared to Protagenic Therapeutics' net margin of -660.61%. Yumanity Therapeutics' return on equity of -101.81% beat Protagenic Therapeutics' return on equity.
Protagenic Therapeutics has higher earnings, but lower revenue than Yumanity Therapeutics. Protagenic Therapeutics is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
Protagenic Therapeutics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.
Yumanity Therapeutics received 14 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.
In the previous week, Protagenic Therapeutics had 1 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 1 mentions for Protagenic Therapeutics and 0 mentions for Yumanity Therapeutics. Yumanity Therapeutics' average media sentiment score of 0.00 equaled Protagenic Therapeutics'average media sentiment score.
8.0% of Protagenic Therapeutics shares are held by institutional investors. Comparatively, 25.1% of Yumanity Therapeutics shares are held by institutional investors. 37.0% of Protagenic Therapeutics shares are held by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Protagenic Therapeutics beats Yumanity Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Yumanity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Yumanity Therapeutics Competitors List
Related Companies and Tools
